Biosimilars
Biosimilars have similar, but not identical, structures to branded biologic drugs. Being comparable, but not interchangeable, they can differ in cost-effectiveness and accessibility. Increased competition, however, can reduce healthcare system costs.
The Impact of Biosimilars on Markets
24 May 2010
The availability of biosimilars — ‘copies’ of biologics — is very recent and limited so far to only a few products. Projecting the impact on markets…
Biosimilars: How Much Entry and Price Competition Will Result?
1 December 2010
This publication reports on a seminar intended to encourage further thought about the distinguishing characteristics of the market for biosimilars and the implications of these for…
The Market for Biosimilars: Evolution and Policy Options
1 November 2008
The authors point out that biopharmaceuticals are more complex agents than conventional chemical entities and therefore are more difficult to replicate after patent expiry. Off-patent versions…
Brand Names in Prescribing
1 September 1976
To present a balanced view of the brand name/generic controversy and the associated field of bioavailability. Many have discussed these problems; scientists, politicians, industrialists, legislators, hospital…